- Home
- STX vs SNY Comparison
STX vs SNY Comparison
Compare STX & SNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | STX | SNY |
|---|---|---|
| Founded | 1978 | 1994 |
| Country | Singapore | France |
| Employees | 30000 | 74846 |
| Industry | Electronic Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 187.0B | 110.4B |
| IPO Year | 2002 | N/A |
Fundamental Metrics
Financial Performance| Metric | STX | SNY |
|---|---|---|
| Price | $832.52 | $42.61 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 21 | 5 |
| Target Price | ★ $604.14 | $58.00 |
| AVG Volume (30 Days) | ★ 4.0M | 2.6M |
| Earning Date | 04-28-2026 | 04-23-2026 |
| Dividend Yield | 0.46% | ★ 3.47% |
| EPS Growth | ★ 328.48 | N/A |
| EPS | ★ 8.29 | N/A |
| Revenue | ★ $7,384,000,000.00 | N/A |
| Revenue This Year | $27.73 | $3.49 |
| Revenue Next Year | $25.06 | $6.10 |
| P/E Ratio | $100.25 | ★ $6.14 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $103.73 | $42.48 |
| 52 Week High | $841.31 | $53.36 |
Technical Indicators
Market Signals| Indicator | STX | SNY |
|---|---|---|
| Relative Strength Index (RSI) | 80.61 | 30.79 |
| Support Level | $364.17 | N/A |
| Resistance Level | N/A | $48.76 |
| Average True Range (ATR) | 37.30 | 0.72 |
| MACD | 13.49 | -0.42 |
| Stochastic Oscillator | 92.28 | 4.22 |
Price Performance
Historical ComparisonAbout STX Seagate Technology Holdings PLC (Ireland)
Seagate Technology is a leading supplier of hard disk drives for data storage to the enterprise and consumer markets. It forms a practical duopoly in the market with its chief rival, Western Digital; they are both vertically integrated.
About SNY Sanofi ADS
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for over 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.